Last reviewed · How we verify
F901318 Dose level C oral
At a glance
| Generic name | F901318 Dose level C oral |
|---|---|
| Also known as | antifungal agent |
| Sponsor | F2G Biotech GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (PHASE1)
- Single Ascending Oral Dose Study of F901318 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |